Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam

Eur J Clin Pharmacol. 1987;32(1):89-91. doi: 10.1007/BF00609964.

Abstract

Piroxicam (20 mg once daily) was administered orally to six healthy young volunteers for 15 days. Trough steady-state levels of piroxicam and 5'-hydroxypiroxicam were 5.5 and 1.2 micrograms/ml, respectively. Piroxicam's plasma half-life (54.9 h) was significantly shorter than that of 5'-hydroxypiroxicam (70.5 h). Percent unbound piroxicam and 5'-hydroxypiroxicam in plasma at steady-state averaged 1.10 and 8.07 respectively. An average of 25.2% of the dose was recovered in urine as 5'-hydroxypiroxicam; approximately two-thirds (17.2%) in the form of the glucuronide conjugate. Average steady-state plasma levels (Css) of piroxicam (7.0 micrograms/ml) were significantly higher than predicted from a previously reported single dose study (5.3 micrograms/ml).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biotransformation
  • Female
  • Half-Life
  • Humans
  • Kinetics
  • Male
  • Piroxicam / administration & dosage
  • Piroxicam / analogs & derivatives*
  • Piroxicam / blood
  • Piroxicam / metabolism*
  • Protein Binding
  • Time Factors

Substances

  • Piroxicam
  • 5'-hydroxypiroxicam